Applied Therapeutics, Inc. (APLT): Price and Financial Metrics


Applied Therapeutics, Inc. (APLT): $22.44

-1.25 (-5.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

APLT Stock Price Chart Interactive Chart >

Price chart for APLT

APLT Price/Volume Stats

Current price $22.44 52-week high $49.88
Prev. close $23.69 52-week low $13.58
Day low $21.69 Volume 212,300
Day high $23.61 Avg. volume 112,701
50-day MA $18.43 Dividend yield N/A
200-day MA $20.57 Market Cap 585.26M

Applied Therapeutics, Inc. (APLT) Company Bio


Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY


APLT Latest News Stream


Event/Time News Detail
Loading, please wait...

APLT Latest Social Stream


Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about Applied Therapeutics Inc that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Applied Therapeutics Gets Fast Track Designation from FDA

Applied Therapeutics says drug candidate to treat rare disorder affecting sugar processing gets fast track designation from the FDA.

Yahoo | June 17, 2021

Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AT-007 for the treatment of Galactosemia, a rare metabolic disease. AT-007 is the Company’s central nervous system-penetrant Aldose Reductase

Yahoo | June 17, 2021

Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 1:20 p.m. ET. Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast. About Applied Therapeutics Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecula...

Yahoo | June 1, 2021

2 “Strong Buy” Stocks Trading at Steep Discounts

reward combination will work toward long-term advantage. So, how are investors supposed to distinguish between the names poised to get back on their feet and those set to remain down in the dumps? That’s what the pros on Wall Street are here for. Using TipRanks’ database, we pinpointed two beaten-down stocks the analysts believe are gearing up for a rebound.

Michael Marcus on TipRanks | May 20, 2021

Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at the upcoming 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) taking place April 13-16, 2021. The abstract and presentation include a cross-sectional analysis of nineteen pediatric patients with Classic Galactosemia, characterizing progressive worsening of the central nervous system (CNS) phenotype with age. “We are pleased to share this important data with the medical community,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Appl...

Yahoo | April 7, 2021

Read More 'APLT' Stories Here

APLT Price Returns

1-mo 32.62%
3-mo 10.38%
6-mo -2.18%
1-year -53.48%
3-year N/A
5-year N/A
YTD 1.95%
2020 -19.32%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.1529 seconds.